Breast Cancer Clinical Trial

Alcohol and Breast Cancer (ABC) Trial

Summary

This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer taking an aromatase inhibitor

The names of the study exposures involved in this study are:

White wine
White grape juice

View Full Description

Full Description

This research study is trying to to help understand whether light alcohol consumption causes short-term changes in the levels of estrogen, progesterone and testosterone, called sex hormones, among postmenopausal women with estrogen and/or progesterone receptor positive breast cancer taking estrogen-blocking medications called aromatase inhibitors.

The research study procedures include one screening visit to obtain informed consent, four study visits with blood draws, and ten weekly phone calls and online questionnaires over the ten weeks of the study.

This research study involves 10 weeks of participation, including 3 weeks consuming one serving of white wine daily, 3 weeks consuming one serving of white grape juice daily, and 2 weeks of drinking neither alcohol nor grape juice before each of these 3-week drinking periods.

In this experimental study, participants will be asked to drink white wine and white grape juice, which are not consumed as the standard of care. The U.S. Food and Drug Administration (FDA) has not approved alcohol as a treatment for any disease.

It is expected that about 20 women will take part in this research study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

ER+ breast cancer
Female sex at birth
Postmenopausal, either natural or induced
Self-reported consumption of at least one alcoholic drink per week but not more than one serving per day
Currently prescribed aromatase inhibitors including anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®)
Documented liver function test results below 1.5X the upper limit of normal within 12 months of screening

Exclusion Criteria:

Self-reported consumption of more than one drink per day, a previous or current history of alcohol abuse based on standard questionnaires (AUDIT≥8), or consumption of more than 4 or more drinks in one day within the last 6 months
Currently undergoing cytotoxic chemotherapy or radiation or planned in the next two months
Any surgery planned in the next two months
Alcohol flushing syndrome
Current use of any pharmaceutical agent contraindicated with alcohol, including warfarin, dual antiplatelet therapy, and metronidazole
Hemoglobin A1c>8% or a fasting glucose result above 180 mg/dL within 6 months of screening
Unable to speak or understand English
Unable to understand and provide informed consent, as judged by the study team

Study is for people with:

Breast Cancer

Estimated Enrollment:

20

Study ID:

NCT05423730

Recruitment Status:

Recruiting

Sponsor:

Beth Israel Deaconess Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States More Info
Kenneth Mukamal, MD, MPH
Contact
617-754-1409
[email protected]
Kenneth Mukamal, MD, MPH
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

20

Study ID:

NCT05423730

Recruitment Status:

Recruiting

Sponsor:


Beth Israel Deaconess Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider